The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANEB | -67.02% | N/A | N/A | -93% |
| S&P | +12.9% | +73.65% | +11.66% | +61% |
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm’s product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
No news articles found for Anebulo Pharmaceuticals.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $41.50M | -4.8% |
| Market Cap / Employee | $13.83M | 0.0% |
| Employees | 3 | 0.0% |
| Net Income | -$1,999.40K | 18.8% |
| EBITDA | -$2,619.91K | -1.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.04M | -39.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.16% | 2.5% |
| Return On Invested Capital | -117.03% | -13.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,313.20K | 6.6% |
| Operating Free Cash Flow | -$1,313.20K | 6.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.57 | 4.39 | 8.81 | 4.26 | -81.43% |
| Price to Tangible Book Value | 3.57 | 4.39 | 8.81 | 4.26 | -81.43% |
| Enterprise Value to EBITDA | -16.41 | -17.22 | -21.03 | -35.25 | 87.55% |
| Return on Equity | -83.4% | -109.7% | -145.1% | -69.7% | -2.52% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
